Guanze Medical Information Industry (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock code：2427)

(1) CHANGE OF DIRECTORS; (2) CHANGE OF COMPOSITION OF BOARD COMMITTEES; (3) CHANGE OF CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD; AND (4) CHANGE OF AUTHORISED REPRESENTATIVE

RESIGNATION OF DIRECTORS

The board (the "**Board**") of directors (the "**Directors**") of Guanze Medical Information Industry (Holding) Co., Ltd. (the "**Company**") announces that the following Directors have tendered their resignations with effect from 1 July 2026 in order to devote more time to his/her other business arrangements and engagements:

(a) Mr. Guo Zhenyu ("**Mr. Guo**") has resigned as an executive Director of the Company; and

(b) Ms. Meng Cathy ("**Ms. Meng**") has resigned as a non-executive Director and a member of the nomination committee of the Board (the "**Nomination Committee**").

The Board would like to take this opportunity to express its sincere gratitude to each of Mr. Guo and Ms. Meng for their valuable contributions to the Company during their tenure of office.

Each of Mr. Guo and Ms. Meng has confirmed that there are no matters relating to his/her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**").

APPOINTMENT OF DIRECTORS

The Board further announces that the following persons have been appointed as Directors with effect from 1 July 2026:

(a) Ms. Jiang Zeman (江澤曼) ("**Ms. Jiang**") has been appointed as an executive Director, chairperson of the Nomination Committee and a member of remuneration committee of the Board (the "**Remuneration Committee**"); and

(b) Ms. Qin Jingying (覃景瑩) ("**Ms. Qin**") has been appointed as an executive Director.

The biographical details of the newly appointed Directors are set out below:

Ms. Jiang Zeman (江澤曼)

Ms. Jiang, aged 35, is the Director, Vice President, and General Manager of the Risk Control and Compliance Center of Funde Holding (Group) Co., Ltd. (富德控股(集團)有限公司) ("**Funde Group**", the holding company of the Company's controlling shareholder). She is also responsible for the Audit and Inspection Center and assists in managing the Board Planning Office of Funde Group.

Since June 2023, she has served as a Supervisor of Shenzhen Qianhai Funde Energy Investment Holding Co., Ltd. (深圳市前海富德能源投資控股有限公司) (a controlling subsidiary of Funde Group). Since October 2025, she has served as a Director of Shenzhen Funde Energy Technology Holding Co., Ltd. (深圳市富德能源科技控股有限公司) (a controlling subsidiary of Funde Group).

From September 2015 to April 2023, Ms. Jiang practiced at Beijing Junzejun (Shenzhen) Law Firm (北京市君澤君(深圳)律師事務所). Ms. Jiang obtained a Bachelor's degree in Law from Shantou University in June 2015 and received the Legal Professional Qualification Certificate issued by the Ministry of Justice of the People's Republic of China in August 2015.

She possesses a solid professional foundation and extensive management experience in corporate risk control, compliance system development, audit supervision, group governance, and complex commercial legal matters.

Ms. Jiang has entered into a service agreement with the Company pursuant to which her initial term of service commences from 1 July 2026 for a term of three years, unless terminated by either party giving to the other not less than one month's notice in writing and in accordance to the terms of the service agreement. Ms. Jiang shall hold office only until the following annual general meeting of the Company and shall be eligible for re-election at that meeting. Ms. Jiang's term of office as an Executive Director shall also be subject to retirement by rotation and re-election pursuant to the third amended and restated articles of associations of the Company (the "**Articles**"). Ms. Jiang is not entitled to any director's fee, subject to review by the Remuneration Committee.

Ms. Qin Jingying (覃景瑩)

Ms. Qin, aged 39, is a Director, Vice President, and Financial Controller of Funde Group, and is responsible for the Financial Management Center.

Since June 2024, she has served as a Director of Shenzhen Funde Capital Holding Co., Ltd. (深圳市富德資本控股有限公司) (a controlling subsidiary of Funde Group). Since July 2024, she has served as a Non-executive Director of Funde Securities Co., Ltd. (富德證券有限公司) (a controlling subsidiary of Funde Group).

Ms. Qin obtained a Master's degree in Management from Hunan University in December 2011 and became a non-practicing member of the Chinese Institute of Certified Public Accountants in April 2014. She possesses a solid professional foundation and extensive practical experience in establishing and optimizing corporate financial systems, providing investment analysis support, and risk prevention and control.

Ms. Qin has entered into a service agreement with the Company pursuant to which her initial term of service commences from 1 July 2026 for a term of three years, unless terminated by either party giving to the other not less than one month's notice in writing and in accordance to the terms of the service agreement. Ms. Qin shall hold office only until the following annual general meeting of the Company and shall be eligible for re-election at that meeting. Ms. Qin's term of office as an Executive Director shall also be subject to retirement by rotation and re-election pursuant to the Articles. Ms. Qin is not entitled to any director's fee, subject to review by the Remuneration Committee.

Save as disclosed above, each of Ms. Jiang and Ms. Qin confirms that as at the date of this announcement, she (i) did not hold any directorships in the last three years in public companies the securities of which are listed on any securities market in Hong Kong or overseas; (ii) does not hold any other positions with any member of the Group; (iii) does not have any relationships with any Directors, senior management or substantial or controlling Shareholders of the Company; (iv) does not have any interests in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (v) is not aware of any additional information that is required to be disclosed pursuant to the requirements under Rule 13.51(2)(h) to Rule 13.51(2)(v) of the Listing Rules.

The Board would like to take this opportunity to express its warmest welcome to Ms. Jiang and Ms. Qin for joining the Board.

CHANGE OF COMPOSITION OF BOARD COMMITTEES

Following the resignations and appointments of Directors as disclosed above, with effect from 1 July 2026, the composition of the Remuneration Committee and Nomination Committee had been changed as follows:

(a) Ms. Meng has ceased to be a member of the Nomination Committee;

(b) Mr. Meng Xianzhen ("**Mr. Meng**") has ceased to be a member of the Remuneration Committee;

(c) Ms. Jiang has been appointed as the chairperson of the Nomination Committee and a member of the Remuneration Committee; and

(d) Dr. Zhao Bin ("**Dr. Zhao Bin**") has been redesignated from the chairman of the Nomination Committee to a member of the Nomination Committee.

CHANGES OF CHIEF EXECUTIVE OFFICER AND CHAIRMAN OF THE BOARD

The Board further announces that, with effect from 1 July 2026, Ms. Jiang has been appointed as the Chief Executive Officer of the Company and the Chairman of the Board, and Mr. Meng has ceased to serve as the Chief Executive Officer and the Chairman of the Board, but will continue to serve as an executive Director.

Code Provision C.2.1 of the Corporate Governance Code as set out in the Part 2 of Appendix C1 to the Listing Rules ("**CG Code**") provides that the roles of chairman and chief executive officer should be separated and should not be performed by the same individual. Despite the deviation from Code Provision C.2.1, considering the fact that Ms. Jiang has suitable management capabilities along with her understanding of the Group's business and strategy, the Board believes that vesting the role of the chairman and the duties of a chief executive officer in Ms. Jiang can facilitate the execution of the Group's business strategies and boost effectiveness of its operation. Therefore, the Board considers that the deviation from Code Provision C.2.1 of the CG Code will not be inappropriate in such circumstance.

CHANGE OF AUTHORISED REPRESENTATIVE

The Board announces that Mr. Meng has ceased to act as an authorized representative ("**Authorised Representative**") of the Company for the purpose of Rule 3.05 of the Listing Rules. The Board further announces that Ms. Jiang has been appointed as an Authorised Representative with effect from 1 July 2026.

By Order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Jiang Zeman
Chairman of the Board

Hong Kong, 30 June 2026

As at the date of this announcement, the executive Directors are Ms. Jiang Zeman, Ms Qin Jingying and Mr. Meng Xianzhen, the independent non-executive Directors are Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond.